Stocks
Immunomedics Financial Statements (IMMU) |
||||||||||
| Immunomedicssmart-lab.ru | % | 2015 | 2016 | 2017 | 2018 | 2019 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.08.2015 | 18.08.2016 | 16.08.2017 | 23.08.2018 | 27.02.2020 | 05.08.2020 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 5.65 | 3.23 | 3.09 | 2.16 | 0.295 | 40.1 | |||
| Operating Income, bln rub | -46.2 | -59.0 | -79.1 | -141.0 | -324.8 | -270.0 | ||||
| EBITDA, bln rub | ? | -45.3 | -57.9 | -146.8 | -249.1 | -321.0 | -259.6 | |||
| Net profit, bln rub | ? | -48.0 | -59.0 | -153.2 | -273.8 | -357.2 | -319.0 | |||
| OCF, bln rub | ? | -39.0 | -48.5 | -62.3 | -134.0 | -222.4 | -205.4 | |||
| CAPEX, bln rub | ? | 0.924 | 2.23 | 1.84 | 9.97 | 6.85 | 2.65 | |||
| FCF, bln rub | ? | -39.9 | -50.7 | -64.1 | -143.9 | -229.3 | -208.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 9.87 | 7.59 | 30.0 | 43.3 | 70.3 | 306.8 | ||||
| Cost of production, bln rub | 42.0 | 54.7 | 52.3 | 99.9 | 254.9 | 3.34 | ||||
| R&D, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 210.0 | ||||
| Interest expenses, bln rub | 2.09 | 5.48 | 5.48 | 23.3 | 40.3 | 55.5 | ||||
| Assets, bln rub | 105.8 | 57.0 | 162.6 | 664.2 | 671.7 | 1 077 | ||||
| Net Assets, bln rub | ? | -3.91 | -56.8 | -58.7 | 400.5 | 268.3 | 593.3 | |||
| Debt, bln rub | 182.8 | 134.8 | 209.6 | 245.5 | 262.3 | 272.0 | ||||
| Cash, bln rub | 99.6 | 50.6 | 154.9 | 638.8 | 613.2 | 975.5 | ||||
| Net debt, bln rub | 83.2 | 84.2 | 54.7 | -393.3 | -350.9 | -703.5 | ||||
| Ordinary share price, rub | 4.06 | 2.32 | 8.83 | 23.7 | 21.2 | 87.9 | ||||
| Number of ordinary shares, mln | 93.3 | 94.8 | 104.5 | 153.5 | 193.6 | 225.3 | ||||
| Market cap, bln rub | 379 | 220 | 923 | 3 633 | 4 097 | 19 797 | ||||
| EV, bln rub | ? | 462 | 304 | 978 | 3 239 | 3 746 | 19 093 | |||
| Book value, bln rub | -4 | -57 | -59 | 401 | 268 | 593 | ||||
| EPS, rub | ? | -0.51 | -0.62 | -1.47 | -1.78 | -1.84 | -1.42 | |||
| FCF/share, rub | -0.43 | -0.53 | -0.61 | -0.94 | -1.18 | -0.92 | ||||
| BV/share, rub | -0.04 | -0.60 | -0.56 | 2.61 | 1.39 | 2.63 | ||||
| EBITDA margin, % | ? | -800.9% | -1 790% | -4 748% | -11 555% | -108 819% | -646.6% | |||
| Net margin, % | ? | -849.1% | -1 826% | -4 956% | -12 701% | -121 081% | -794.6% | |||
| FCF yield, % | ? | -10.5% | -23.1% | -6.94% | -3.96% | -5.60% | -1.05% | |||
| ROE, % | ? | 1 227% | 103.9% | 261.0% | -68.4% | -133.2% | -53.8% | |||
| ROA, % | ? | -45.4% | -103.7% | -94.2% | -41.2% | -53.2% | -29.6% | |||
| P/E | ? | -7.89 | -3.72 | -6.02 | -13.3 | -11.5 | -62.1 | |||
| P/FCF | -9.49 | -4.34 | -14.4 | -25.2 | -17.9 | -95.2 | ||||
| P/S | ? | 67.0 | 68.0 | 298.6 | 1 685 | 13 888 | 493.1 | |||
| P/BV | ? | -96.8 | -3.87 | -15.7 | 9.07 | 15.3 | 33.4 | |||
| EV/EBITDA | ? | -10.2 | -5.25 | -6.66 | -13.0 | -11.7 | -73.5 | |||
| Debt/EBITDA | -1.84 | -1.45 | -0.37 | 1.58 | 1.09 | 2.71 | ||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7 930% | ||||
| CAPEX/Revenue, % | 16.4% | 68.9% | 59.4% | 462.6% | 2 322% | 6.60% | ||||
| Immunomedics shareholders | ||||||||||
